

Ozurdex® (dexamethasone intravitreal implant)

When requesting Ozurdex® (dexamethasone intravitreal implant), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

FDA-approved indications

Ozurdex® (dexamethasone intravitreal implant) is indicated for:

- The treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion.
- The treatment of non-infectious uveitis affecting the posterior segment of the eye.
- The treatment of diabetic macular edema.

Coverage Guidelines

For all approved indications, the individual does not have any of the following contraindications or exclusions to therapy:

- Ocular or periocular infections
- Glaucoma with cup to disc ratios > 0.8
- A torn or ruptured posterior lens capsule

Approval duration: 12 months

Dosing Recommendations

- 0.19mg intravitreal implant

References

1. Ozurdex® prescribing information. Irvine, CA: Allergan, Inc.: September 2014.
2. Dexamethasone. In: DRUGDEX® System. Micromedex 2.0. Greenwood Village, CO; Thompson Reuters (Healthcare). [Accessed April 17, 2018].
3. Schmidt-Erfurth U et al. Guideline for the Management of Diabetic Macular by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017;237:185-222.

4. American Academy of Ophthalmology (2017). Retina Summary Benchmarks for Preferred Practice Guidelines.
5. American Academy of Ophthalmology (2015). Preferred Practice Guidelines: Retinal Vein Occlusion.